12:00 AM
 | 
May 30, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enfortumab vedotin: Phase I data

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and 1.25 mg/kg doses of IV enfortumab vedotin...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >